Skip to content
10-K

Annual Report

Lomond Therapeutics Holdings, Inc.

0001213900-26-044136

← back to feed
Filed
Apr 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Apr 14, 2026 32.2M sh
Shares Diluted FY 2025 · Dec 31, 2025 31.48M sh
Shares Diluted FY 2025 · Dec 31, 2024 5.18M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$22.78M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$12.04M
Short Term Investments FY 2025 · Dec 31, 2025 $11.24M
Cash And Equivalents FY 2025 · Dec 31, 2025 $13.2M
Cash And Equivalents restated FY 2025 · Dec 31, 2024 $28.42M
Stockholders Equity FY 2025 · Dec 31, 2025 $21.31M
Stockholders Equity FY 2025 · Dec 31, 2024 $23.76M
Stockholders Equity restated FY 2025 · Dec 31, 2023 −$5.52M
Current Liabilities FY 2025 · Dec 31, 2025 $9.51M
Current Liabilities FY 2025 · Dec 31, 2024 $2.55M
Total Liabilities FY 2025 · Dec 31, 2025 $9.51M
Total Liabilities FY 2025 · Dec 31, 2024 $5.5M
Current Assets FY 2025 · Dec 31, 2025 $27.27M
Current Assets FY 2025 · Dec 31, 2024 $29.25M
Total Assets FY 2025 · Dec 31, 2025 $30.82M
Total Assets FY 2025 · Dec 31, 2024 $29.25M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.75
Eps Diluted FY 2025 · Dec 31, 2024 −$3.30
Eps Basic FY 2025 · Dec 31, 2025 −$0.75
Eps Basic FY 2025 · Dec 31, 2024 −$3.30
Sga Expense FY 2025 · Dec 31, 2025 $4.2M
Sga Expense FY 2025 · Dec 31, 2024 $1.94M
Rd Expense FY 2025 · Dec 31, 2025 $20.26M
Rd Expense FY 2025 · Dec 31, 2024 $14.34M
Net Income FY 2025 · Dec 31, 2025 −$23.53M
Net Income FY 2025 · Dec 31, 2024 −$17.09M
Operating Income FY 2025 · Dec 31, 2025 −$24.46M
Operating Income FY 2025 · Dec 31, 2024 −$16.28M